Clinical enrollment assay to detect preexisting neutralizing antibodies to AAV6 with demonstrated transgene expression in gene therapy trials

Recombinant adeno-associated virus (AAV) vectors are the leading platform for gene delivery for a variety of clinical applications. Patients with preexisting antibodies to AAV are currently excluded from most AAV gene therapy trials to avoid vector neutralization and ensure response to therapy. Anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Liching, Ledeboer, Annemarie, Pan, Yonghua, Lu, Yanmei, Meyer, Kathleen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9935387/
https://www.ncbi.nlm.nih.gov/pubmed/35778500
http://dx.doi.org/10.1038/s41434-022-00353-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9935387/
https://www.ncbi.nlm.nih.gov/pubmed/35778500
http://dx.doi.org/10.1038/s41434-022-00353-2

Ejemplares similares